INTRODUCTION
============

Natural evolution, based on the selection of beneficial mutations within a population of genetic variants, has created the amazing diversity of life on our planet. While natural selection works on whole genomes, the evolution of individual proteins can be tracked by the analysis of intra-species polymorphisms and inter-species divergence. A fascinating example for the evolution of a single protein by mutation and selection is the affinity maturation of antibodies in B cells ([@B1]). Developing B cells activate and diversify their *immunoglobulin* (*Ig*) genes by recombination, but only cells encoding antibodies with antigen-binding specificity are stimulated to expand after antigen challenge. These B cells hypermutate their *Ig* genes and cycles of hypermutation and selection continue until antibodies of sufficiently high antigen-binding affinity emerge.

Recombinant DNA technologies are able to recapitulate the evolution of proteins by mutagenesis and selection *in vitro*. Most approaches combine the expression of diverse gene libraries in phage, bacteria or translation systems with selection for the encoded proteins ([@B2],[@B3]). If the structure-function relationship of a protein is sufficiently understood, site-directed mutagenesis of critical amino acids can be used instead or in addition to random mutagenesis ([@B4]). The potential of *in vitro* protein evolution is illustrated by the example of the green fluorescent protein (GFP) ([@B5]) which could be changed into yellow, cyan or blue variants by random and site-directed mutagenesis and selection *in vitro* ([@B6; @B7; @B8]).

Affinity maturation of antibodies can be simulated *ex vivo* in cultures of hypermutating B cell lines by the enrichment of cells expressing antigen-specific antibodies ([@B9],[@B10]). B cell lines could also be used for the optimization of non-immunoglobulin proteins, if the hypermutating activity were directed toward transfected transgenes and cells carrying beneficial mutations were selected. Advantages of this approach are the possibilities to generate an enormous amount of genetic diversity and to select for improved protein variants within a living cell culture. It was recently reported that a gene encoding a red fluorescent protein (FP) was transferred into the hypermutating human B cell line RAMOS, and the selection of cells emitting red-shifted fluorescence yielded the most far red-shifted FP protein known to date ([@B11]).

Despite this impressive result, hypermutation is difficult to control in RAMOS, because transgenes usually integrate at random chromosomal sites outside the hypermutating *Ig* loci. In contrast, transgenes can be easily inserted into the *Ig* loci of the chicken B cell line DT40 ([@B12]). DT40 diversifies its rearranged *Ig light chain* gene by *pseudo V* (ψ*V*) gene-templated gene conversion ([@B13]), but if gene conversion is blocked due to the inactivation of *RAD51* paralogues or the deletion of gene conversion donors, hypermutation occurs ([@B14],[@B15]). *Ig* gene diversification by conversion or hypermutation requires expression of the *AID* gene ([@B15],[@B16]). Based on these results, we reasoned that transgenes inserted into the *Ig* loci of DT40 without nearby gene conversion donors would be diversified by hypermutation in AID positive cells. To test this hypothesis, we inserted the *enhanced GFP* (*eGFP*) gene ([@B17]) into the rearranged *Ig light chain* locus and searched for cells displaying increased fluorescence. Only three rounds of fluorescence activated cell sorting (FACS) were sufficient to isolate cells expressing eGFP variants whose fluorescent intensity appears to be superior to the best GFPs currently available for vertebrate cell labeling.

MATERIALS AND METHODS
=====================

Cell lines
----------

Cells were cultured in chicken medium (RPMI-1640 or DMEM/F-12 with 10% fetal bovine serum, 1% chicken serum, 2 mM [l]{.smallcaps}-glutamine, 0.1 mM β-mercaptoethanol and penicillin/streptmycin) at 41°C with 5% CO2. The AID expressing DT40 clones, AID^R1^CL1 and AID^R1^CL2, used in the study for hypermutation were derived from the AID knockout cell clone DT40^Cre1^AID^−/−^ ([@B16]) by stable transfection of a floxed *AID*---IRES (*internal ribosome entry site*)---gpt (guanine phosphoribosyl transferase) bicistronic cassette. The IRES sequence was derived from Encephalomyocarditis virus. Because the bi-cistronic cassette is driven by the strong β-*actin* promoter and since *AID* is the first gene downstream of the promoter, AID protein expression in AID^R1^CL1 and CL2 is higher than in wild-type DT40 cells (unpublished data). The cell clones express the Cre recombinase as a MerCreMer fusion protein which is inactive due to its retention in the endoplasmic reticulum in the absence of estrogen derivatives ([@B18]). However, since background activity of MerCreMer can lead to undesired excision of the floxed AID-gpt expression cassette during prolonged culture, we selected for cells retaining *AID* by culturing in media containing 0.5 µg/ml of mycophenolic acid for 3 days following each preparative FACS sort.

An AID negative subclone of AID^R1^Cl1 was generated by culturing the cells in chicken medium containing 1 µM 4-hydroxitamoxifen (SIGMA) for 2 days and subsequent subcloning.

Targeted integration of transgenes into the rearranged Ig locus
---------------------------------------------------------------

Cells were transfected by electroporation using the Gene Pulser Xcell (BIO-RAD) at 25 µF and 700 V ([@B16]) and stable transfectants were selected for using 1 µg/ml of puromycin. Transfectants having integrated the pHypermut1- or pHypermut2-derived constructs by targeted integration were identified by PCR using primer pairs P1/P2 and P1/P3, respectively. The frequency of targeted integration after transfection of *pHypermut* constructs was consistently more than 70% (data not shown). Since the constructs can target either the rearranged or the unrearranged Ig locus of DT40, integration into the rearranged Ig light chain locus was verified by PCR amplification of the *VJ* intervening sequence of the unrearranged locus using primer pairs of *P4/P5*.

Flow cytometry
--------------

To quantify the appearance of GFP negative cells within proliferating cultures, the AID^R1^IgL^eGFP1^, AID^−/−^IgL^eGFP1^ and ψVAID^R1^IgL^eGFP^ clones were subcloned by limited dilution, and 24 subclones of each were analyzed 2 weeks after subcloning by FACS. The preparative FACS sorts to select cells of increased fluorescence were performed using the MoFlo high-speed cell sorter (Cytomation).

PCR, cloning and sequencing
---------------------------

The screenings for targeted integration and the amplification of the *eGFP* transgenes were performed with the expand long template PCR system (Roche) under the following conditions: 2 min of initial incubation at 93°C; 35 cycles consisting of 10 s at 93°C, 30 s at 65°C and 5 min (plus an added 20 s per cycle) at 68°C and a final elongation step of 7 min at 68°C. The primer pair for the amplification of the *eGFP* gene from sorted cells was *P6*/*P7*. The PCR products were digested with HindIII and XbaI, cloned into the *pUC119* plasmid vector and sequenced using primers *P8* and *P9*. The mutated *eGFP* genes were then amplified using *Pfu* Ultra hotstart polymerase (Stratagene) and primer pair *P10*/*P11*, digested by AvrII and cloned into the NheI site of *pHypermut2*. The orientation and the sequence of the mutant *eGFPs* in *pHypermut2* was verified by sequencing using primers *P12* and *P13*.

Site-directed mutagenesis
-------------------------

To combine the codon changes found in different eGFP variants, we designed primers (*P14*--*P26*) which included the intended mutations in the center of the primer sequence. In the first step, parts of the eGFP gene were amplified by PCR using at least one mutation-containing primer. In the second step, PCR fragments containing mutations were mixed with other PCR fragments to cover the full eGFP coding sequence. This mixture served as a template for chimeric PCR using the primer pair of P10/P11. The full length mutant eGFP PCR fragments were digested with AvrII and cloned into the NheI site of pHypermut2. The orientation and the sequence of the mutant *eGFPs* in *pHypermut2* were confirmed by sequencing.

Primers
-------

*P1* GGGACTAGTAAAATGATGCATAACCTTTTGCACA

*P2* CGATTGAAGAACTCATTCCACTCAAATATACCC

*P3* CCCACCGACTCTAGAGGATCATAATCAGCC

*P4* TACAAAAACCTCCTGCCAGTGCAAGGAGCAGCTGATGGTTTTTACTGTCT

*P5* GGGGGATCCAGATCTGTGACCGGTGCAAGTGATAGAAACT

*P6* GGGAAGCTTTGGGAAATACTGGTGATAGGTGGAT

*P7* GGGTCTAGACCTCTCAGCTTTTTCAGCAGAATAACCTCC

*P8* GGTATAAAAGGGCATCGAGGTCCCCGGCAC

*P9* AGTTCGAGGGCGACACCCTGGTGAACCGCA

*P10* GAACCTAGGGCCACCATGGTGAGCAAGGGCGAGGA

*P11* GAACCTAGGACTTGTACAGCTCGTCCATGCCG

*P12* CCTAGCTCGATACAATAAACGCCATTTGAC

*P13* TGGCTTCGGTCGGAGCCATGGAGATC

*P14* AACGGCATCAAGGcGAACTTCAAGATC

*P15* GATCTTGAAGTTCgCCTTATGCCGTT

*P16* CCCGACCACATGAAGgAGCACGACTTCTTC

*P17* GAAGAAGTCGTGCTcCTTCATGTGGTCGGG

*P18* GATCACATGGTCCTGgTGGAGTTCGTGACC

*P20* GGTCACGAACTCCAcCAGGACCATGTGATC

*P21* GCCGACCACTACCAGgAGAACACCCCCATC

*P22* GATGGGGGTGTTCTcCTGGTAGTGGTCGGC

*P23* CTGAgCACCCAGTCCaCCCTGAgCAAAGAC

*P24* GTCTTTGcTCAGGGtGGACTGGGTGcTCAG

*P25* ATCCTGGGGCACAAGgTGGAGTACAACT

*P26* AGTTGTACTCCAcCTTGTGCCCCAGGAT

Color spectrum
--------------

Excitation and emission spectra were analyzed by the luminescence spectrometer LS50B (Perkin Elmer). One million cells were washed once with PBS, resuspended in 2 ml of PBS, and then used for spectrum analysis. The relative ability to excite by lasers of different wavelengths was measured at fixed emission of 540 nm wavelength. The relative emission intensities at different wavelengths were measured after fixed excitation at 460 nm wavelength.

RESULTS
=======

Targeted integration of the *eGFP* gene into the rearranged *Ig* light chain locus
----------------------------------------------------------------------------------

The *eGFP* coding sequence was inserted into the *pHypermut1* vector and transfected into the DT40 variant, AID^R1^CL1, which is deleted for both alleles of the endogenous *AID* gene and expresses *AID* as a floxed cDNA expression cassette ([@B16]). Clones which had integrated the construct into the rearranged *Ig light chain* locus were identified by PCR. Transcription of the *eGFP* gene in these clones is supposed to be driven by the *Ig light chain* promoter and terminated by the *SV40* polyA signal ([Figure 1](#F1){ref-type="fig"}A). The clones contained two floxed transgenes, the *bsr* marker gene co-inserted in the rearranged *Ig light chain* locus and the *AID-IRES-gpt* gene of the AID^R1^ progenitor clone. To remove the *bsr* marker alone or together with the *AID* expression cassette, Cre recombinase was induced by tamoxifen before subcloning by limited dilution ([@B16]). In this way, AID positive (AID^R1^IgL^eGFP1^) and negative (AID^−/−^IgL^eGFP1^) clones could be isolated which had deleted the *bsr* marker gene from the *light chain* locus. Figure 1.Strategy for artificial evolution of eGFP gene. (**A**) A physical map of the chicken rearranged *Ig light chain* locus, the *pHypermut1-eGFP* targeting construct and the rearranged *Ig light chain* locus after targeted integration and marker excision is shown. The positions of primers used for the identification of targeted integration events are shown by arrows. (**B**) FACS profiles of AID^R1^IgL^eGFP1^ and AID^−/−^IgL^eGFP1^ clones. The average percentages of events falling into the GFP^high^ and GFP^low^ gates based on the measurement of 24 subclones are shown. (**C**) Sorting strategy for cells of increased fluorescence activity.

Evidence for hypermutation of the *eGFP* transgene
--------------------------------------------------

The AID^R1^IgL^eGFP1^ and AID^−/−^IgL^eGFP1^ clones were subcloned by limited dilution and 24 subclones of each were analyzed by FACS for GFP brightness 14 days after subcloning. Subclones of the AID^R1^IgL^eGFP1^ clone contained cell populations showing lower (3.8%) and higher (0.5%) fluorescence than the dominant GFP positive cell population, whereas subclones of the AID^−/−^IgL^eGFP1^ clone consisted only of a homogeneous GFP positive population ([Figure 1](#F1){ref-type="fig"}B). This suggests that the eGFP gene inserted into the rearranged Ig light chain locus is diversified in AID^R1^IgL^eGFP1^ cells giving rise to variants of increased and decreased fluorescent intensity.

Mutation activity of artificial evolution system
------------------------------------------------

To analyze the mutation spectrum of the eGFP transgenes, the coding sequence was amplified by PCR from AID^R1^IgL^eGFP1^ and AID^−/−^IgL^eGFP1^ cells 6 weeks after subcloning, cloned into a plasmid vector and sequenced. A total of 13 nt changes were found within the 0.7 kb eGFP coding region of 39 sequences from the AID^R1^IgL^eGFP1^ clone ([Table 1](#T1){ref-type="table"}). Assuming a DT40 doubling time of 10 h, the mutation rate of the eGFP coding region in the rearranged Ig light chain locus of AID^R1^IgL^eGFP1^ cells is approximately 4.7 × 10^−6^ mutations per base pair and division. This mutation frequency is approximately three times lower than the mutation rate of the rearranged *VJ* segment in the pseudogene deleted ψV^−^AID^R^ cell line ([@B15]) perhaps reflecting the lower incidence of hypermutation hotspots in the *eGFP* sequence. In both cases, the majority of mutations occurred at *C*/*G* base pairs ([Table 1](#T1){ref-type="table"}). Only 1 nt change which possibly represents a PCR artifact was found in 26 sequences of the AID^/^IgL^eGFP1^ clone confirming that the mutation activity of the *eGFP* transgene is dependent on AID. Table 1.Mutation profileCell sourceGeneMutationsNumber of sequencesMutations/ sequenceMutations atDuplicationDeletionCGATAID^−/−^IgLe^GFP1^6-week cultureeGFP (723 bp)1260.04001000AID^R1^IgL^eGFP1^6-week cultureeGFP (723 bp)13390.33580010AID^R1^IgL^eGFP1^Sort IeGFP (723 bp)[^a^](#TF1){ref-type="table-fn"}15950.16861000AID^R1^IgL^eGFP1^Sort IpolyA-L (300 bp)[^a^](#TF1){ref-type="table-fn"}88950.931870000AID^R1^IgL^eGFP1^Sort IIIeGFP (723 bp)221852.60130936400[^2]

Sorting and sequence analysis of cells displaying increased fluorescence
------------------------------------------------------------------------

The FACS analysis suggested that a few cells within the AID^R1^IgL^eGFP1^ culture had accumulated mutations which increased either the abundance or the fluorescent intensity of the *eGFP* protein. To enrich these cells, 10 million AID^R1^IgL^eGFP1^ cells were sorted by preparative FACS using a gate which included only the 0.05% brightest cells ([Figure 1](#F1){ref-type="fig"}C). The cells collected by the FACS sort were expanded and cycles of preparative cell sorting and expansion were repeated twice. Three consecutive sorts were performed independently for three AID^R1^IgL^eGFP1^ subclones.

To trace the rise of mutations responsible for the increased fluorescence, the coding sequences of the *eGFP* genes were amplified by PCR from cells after the first and the third sort, cloned into a plasmid vector and sequenced. Unexpectedly, few mutations and no obvious mutation signatures were found in the *eGFP* coding sequence after the first sort ([Table 1](#T1){ref-type="table"}) despite the fact that the sorted cells displayed increased fluorescence ([Figure 1](#F1){ref-type="fig"}C). We therefore extended the sequence analysis to the region downstream of the *eGFP* coding sequence by primer walking. This analysis revealed frequent mutations at the splice donor site of the *Ig light chain* leader intron (88 mutations/95 seq) ([Figure 2](#F2){ref-type="fig"}A, [Table 1](#T1){ref-type="table"}). Although the role of these mutations downstream of the *eGFP* polyA signal remains speculative, it is possible that they enhance fluorescence by increasing *eGFP* mRNA stability. Figure 2.Mutations downstream and within the *eGFP* transgene. (**A**) Mutations identified at the exon/intron border of the *Ig light chain* leader sequence. The number of times a mutation was found is shown by superscript. (**B**) Mutations within the *eGFP* coding sequence. Mutations were mapped below the reference eGFP sequence together with the corresponding amino acid codons. The *eGFP* sequence which we used had one codon (*Val*) inserted next to the start codon to yield an optimal translation-initiation sequence (Kozak motif). This *Val* was numbered as codon 1a according to Crameri ([@B26]) for the easier comparison to wild-type *GFP* and previously reported *GFP* mutants. (**C**) Pedigrees for the evolution of the *eGFP* transgenes in culture. The number of times each sequence was found within each subclone is indicated at the right side of the circles. The amino acid changes of each step are shown beside the arrows. Sequences identified in more than one subclone are named *v1*--*v9*.

In contrast, most of the sequences after the third sort showed mutations in the *eGFP* coding sequence (221 mutations/85 seq) ([Figure 2](#F2){ref-type="fig"}B, [Table 1](#T1){ref-type="table"}). Comparison of the sequences of each sorted subclone allowed us to reconstruct evolutionary trees showing the stepwise accumulation of *eGFP* codon changes ([Figure 2](#F2){ref-type="fig"}C). Many of the codon changes were not shared by different subclones and their functional significance remains uncertain. However, a number of codon changes occurred independently in different subclones suggesting that they are related to the increased fluorescence of the sorted cells. Mutated *eGFP* sequences which were found more than once were named *GFP* variants (*GFPv1--*9).

Development of a new vector for transgene evolution in DT40
-----------------------------------------------------------

Although we were able to use *pHypermut1* for the enhancement of eGFP, this vector is not ideally suited for transgene evolution in DT40, as mutations outside the transgene coding region had apparently been selected for after the first sort. We therefore developed a new targeting vector named pHypermut2 in which the expression of the transgene is unlikely to be influenced by mutations of the rearranged Ig light chain gene, because transgene transcription is driven by the Rous sarcoma virus (RSV) promoter in the opposite direction of the *light chain* gene ([Figure 3](#F3){ref-type="fig"}A). *pHypermut2* allows transgenes to be cloned into multiple cloning sites (NheI, EcoRV and BglII). The vector\'s puromycin resistance (*puroR*) cassette, located downstream of the transgene can be excised by Cre recombinase ([@B19]), but it is unlikely to interfere with transgene transcription or mutagenesis. A convenient feature of *pHypermut2* is the presence of a SpeI site upstream of the RSV promoter which can be used for the insertion of gene conversion donor sequences ([@B20]). Figure 3.Hypermutation of transgenes using *pHypermut2*. (**A**) Plasmid map of *pHypermut2* vector. Target genes for artificial evolution can be cloned into the NheI, EcoRV or BglII sites. Potential gene conversion donor sequences can be cloned into the SpeI site. (**B**) A physical map of the rearranged *Ig light chain* locus, the *pHypermut2*-*eGFP* construct and the rearranged *Ig light chain* locus after targeted integration. The positions of primers used for the identification of targeted integration events are shown by arrows. (**C**) FACS profile of the ψV^−^AID^R1^IgL^eGFP^ clone having integrated the *pHypermut2-eGFP* construct into the rearranged *Ig light chain* locus after 2 weeks culture. The average percentage of events falling into the GFP^low^ gate based on the measurement of 24 subclones is shown.

We inserted the eGFP transgene into pHypermut2, and transfected the construct into the ψV^−^AID^R1^ cell line ([@B15]) ([Figure 3](#F3){ref-type="fig"}B). To estimate the hypermutation rate within the eGFP transgene, one of the stable transfected clones ψV^−^AID^R1^IgL^eGFP^, having integrated the construct into the rearranged *Ig light chain* locus, was subcloned by limited dilution. FACS analysis of 24 subclones after 14 days of culture revealed that on average 10.9% of the cells showed decreased or lost fluorescence ([Figure 3](#F3){ref-type="fig"}C). This result indicates that transgenes inserted by *pHypermut2* into the rearranged *Ig light chain* locus are efficiently diversified by hypermutation.

Confirmation of the variant GFP phenotypes
------------------------------------------

The phenotype of mutations is best confirmed by re-transfection into the genetically stable AID^−/−^ clone and the analysis of transfectants which have integrated the gene as a single copy into the rearranged locus. The *pHypermut2* vector is well suited for this task and all isolated *GFP* variants, as well as the *eGFP* and the *Emerald* ([@B8]) control sequences, were cloned into *pHypermut2.* These constructs were then transfected into AID^−/−^. More than 50% of all stable transfectants had integrated the constructs into the *rearranged light chain* locus and these clones were named according to the inserted transgene (AID^−/−^IgL^eGFP^, AID^−/−^IgL^Emerald^, AID^−/−^IgL^GFPv1^, etc.).

The fluorescent intensity of the different transfectants was compared by FACS ([Figure 4](#F4){ref-type="fig"}A). Two independent transfectants of each variant *GFP* gene were included in the experiment to account for variation among transfectants of the same gene. This analysis revealed that the *Emerald* transfectant was 1.2 times brighter than the *eGFP* transfectant, four of the nine *GFP* variant transfectants (AID^−/−^IgL^GFPv2^, AID^−/−^IgL^GFPv5^, AID^−/-−^gL^GFPv6^ and AID^−/−^IgL^GFPv8^) were brighter than the *eGFP* transfectant. Three variant *GFP* transfectants (AID^−/−^IgL^GFPv5^, AID^−/−^IgL^GFPv6^ and AID^−/−^IgL^GFPv8^) had even higher fluorescent intensity than the *Emerald* transfectant ([Table 2](#T2){ref-type="table"}). Of all variant GFP transfectants, AID^−/−^IgL^GFPv6^ had the highest fluorescent intensity (2.5-fold more than the AID^−/−^IgL^eGFP^) and AID^−/−^IgL^GFPv5^ had the second highest intensity (2.0-fold brighter than the AID^−/−^IgL^eGFP^) ([Figure 4](#F4){ref-type="fig"}A, [Table 2](#T2){ref-type="table"}). Little fluorescent variation was observed among transfectants of the same transgene. Figure 4.Analysis of variant GFP transfectants. (**A**) FACS analysis of control and variant GFP transfectants. The average fluorescence of AID London^−/−^IgL^eGFP^ is indicated by a green line for easier comparison. (**B**) Flow chart of site-directed mutagenesis of GFP variants. (**C**) Relative fluorescence of the transfectants normalized to the fluorescence of AID^−/−^IgL^eGFP^. (**D**) Excitation and emission spectra. (**E**) Image of single cells by fluorescence microscopy. The image of the same single cells is shown with fluorescence activation (upper row) and without fluorescence activation (lower row). Table 2.Amino acid changes and brightness of GFP variantsGFP variantAmino acid changesNumber of sequencesSubcloneRelative brightness[^a^](#TF2){ref-type="table-fn"}eGFPChange from wild-type GFP----1.0 ± 0.11aG, F64L, S65T, H231L, 239SChange from eGFPGFPv1Q80E281, 2, 30.7 ± 0.0GFPv2Q80E, Q184E, A206T191**1.2 ± 0.0**GFPv3Q80E, E124D, L141V, Y237stop1130.3 ± 0.0GFPv4Q80E, S202T41, 20.9 ± 0.1GFPv5Q80E, V163A41**2.0 ± 0.0**GFPv6Q80E, Y145F, S202T32**2.5 ± 0.0**GFPv7Q80E, S208T230.7 ± 0.1GFPv8Q80E, L221V23**1.5 ± 0.3**GFPv9Q80E, L141V, S202I53**1.0 ± 0.1**GFPv10Q80E, Y145F, V163A, S202T----**3.0 ± 0.1**GFPv11 (**GFPnovo1**)Y145F, V163A, S202T----**3.2 ± 0.0**GFPv12 (**GFPnovo2**)Y145F, V163A, S202T, L221V----**3.3 ± 0.0**GFPv13L141V, Y145F, V163A, Q184E, S202T, A206T, L221V----**2.9 ± 0.1**EmeraldChange from wild-type GFP----**1.2**S65T, S72A, N149K, M153T, I167T[^3]

To compare the fluorescent intensity of eGFP and GFPv6 in human cells, the *pHypermut2* constructs of *GFPv6* and *eGFP* were transiently transfected into the human embryonic kidney cell line HEK293T. By FACS analysis, cells transfected with the *GFPv6* construct showed on average more fluorescence than cells transfected with the *eGFP* construct (data not shown**).**

Increased fluorescence by the combination of mutations
------------------------------------------------------

As certain combinations of codon changes were not found among the *GFP* variants, we wondered whether the accumulation of mutations in a single sequence may lead to further enhancement of fluorescent intensity ([Figure 4](#F4){ref-type="fig"}B). At first, we combined *Y145F* and *S202T* of *GFPv6* with *V163A* of *GFPv5* to produce *GFPv10*. Because *GFPv1* harboring the single *Q80E* mutation showed less fluorescent intensity than *eGFP*, we subtracted *Q80E* from *GFPv10* to generate *GFPv11*. We also added *L221V* of *GFPv8* to *GFPv11*, thereby generating *GFPv12*. Finally, we added *Q184E* and *A206T* of *GFPv2* as well as *L141V* of *GFPv9* to *GFPv12* to generate *GFPv13*. These new variants were cloned into *pHypermut2* and inserted into the rearranged *Ig light chain* locus of the clone AID^−/−^.

Transfectants of all new *GFP* variants showed higher fluorescent intensity than AID^−/−^IgL^GFPv6^ by FACS analysis ([Figure 4](#F4){ref-type="fig"}C, [Table 2](#T2){ref-type="table"}). AID^−/−^IgL^GFPv10^ had 3.0-fold higher fluorescent intensity than AID^−/−^IgL^eGFP^, but AID^−/−^IgL^GFPv11^ and AID^−/−^IgL^GFPv12^ were even brighter, displaying 3.2- and 3.3-fold more fluorescence respectively than AID^−/−^IgL^eGFP^. AID^−/−^IgL^GFPv13^ did not surpass the fluorescent intensity of the other variant *GFP* transfectants. The variants *GFPv11* and *GFPv12* which offer the most potential for the labeling of vertebrate cells were named *GFPnovo1* and *GFPnovo2*, respectively.

Spectral properties of the new GFP variants
-------------------------------------------

The excitation and the emission maximum of eGFP are at 488 and 509 nm wavelength, respectively ([@B7],[@B8]). To determine the spectral profiles of the new variant GFP proteins, the control and variant gene transfectants (AID^−/−^IgL^eGFP^, AID^−/−^IgL^Emerald^, AID^−/−^IgL^GFPv5^, AID^−/−^IgL^GFPv6^, AID^−/−^IgL^GFPnovo1^ and the AID^−/−^IgL^GFPnovo2^) were analyzed using a luminescence spectrometer ([Figure 4](#F4){ref-type="fig"}D). This analysis showed that the fluorescent intensity, but not the excitation and emission spectra had been changed in the variant *GFP* transfectants. The lack of mutants showing altered excitation or emission properties is most likely due to our selection strategy which only enriched cells for increased fluorescent intensity.

We also examined cells of the *eGFP, Emerald* and variant *GFP* transfectants by fluorescence microscopy ([Figure 4](#F4){ref-type="fig"}E). Consistent with the FACS and spectrometer analysis, cells of the *GFPv5, GFPv6, GFPnovo1* and *GFPnovo2* transfectants produced brighter images than cells of the *eGFP* and *Emerald* transfectants, but there was no noticeable change of color.

DISCUSSION
==========

We describe here an artificial evolution system in the B cell line DT40 which offers advantages over alternative approaches and could be of generic value for the optimization of many types of proteins in cell culture. The main advantages are the high transgene-specific mutation rates, the easy confirmation of mutant phenotypes and the selection for beneficial mutations within the environment of live vertebrate cells. We have illustrated the utility of the system by generating new GFP variants which display more than 3-fold higher fluorescence activity than the best GFPs currently available for bio-imaging of vertebrate cells.

We have chosen eGFP as a first example for protein evolution in DT40, because the protein has been extensively optimized by random and site-directed mutagenesis and selection of cells displaying brighter fluorescence is straightforward. Only three rounds of FACS sorting during 2 months of culturing were sufficient to isolate mutants of increased fluorescent intensity. Some of the identified mutations are identical to mutations previously reported by others for GFP variants with an altered excitation and/or emission spectrum. For example, the *V163A* codon substitution is included in the *GFP* variants *Cycle3* ([@B7]), *T-Sapphire* ([@B20]), *Venus* ([@B21; @B22; @B23]), *ECFP* ([@B8]) and *W1C* ([@B8]); *Y145F* is shared by the *GFP* variants *Sapphire* ([@B20]), *p4-3* ([@B8]) and *EBFP* ([@B7],[@B8]); *L221V* is shared by *EGFPevo* mutants ([@B24]). It has been proposed that the *V163A* substitution facilitates the correct folding and maturation of GFP ([@B6]). Other amino acid changes such as *S202T* and *A206T* are first described in this study. Although the crystal structure of GFP is resolved ([@B25]) it is not easy to explain the increased fluorescence of our variant *GFP* transfectants without more detailed studies of the encoded mRNAs and proteins. As the configuration of the GFP chromophore has already been optimized, the most likely reason seems to be improved protein maturation or stability. The amino acid substitutions *A206T* and *L221V* are localized in a region known to influence GFP dimerization and their effect might be due to the enhancement of dimer formation, but other effects cannot be ruled out. Regardless of the molecular basis, the increased fluorescence conferred by the new GFP variants and in particular GFPnovo1 and GFPnovo2 should be useful in situations where maximal sensitivity is required for bio-imaging.

Compared to alternative artificial evolution techniques, protein optimization in hypermutating B cell lines like DT40 has the advantage that it is performed within the real life environment of a vertebrate cell. This can be important as the properties of many proteins are affected by *intra-cellular* parameters such as pH and salt concentrations, folding, post-translational modifications and degradation. Although optimization of proteins has been achieved in hypermutating mammalian B cell lines such as Ramos ([@B11]) or 18--81 ([@B24]), DT40 offers the advantages that transgenes can be inserted as single copies into the *Ig light chain* locus and AID expression can be controlled. In the future, transgene diversification in DT40 may be accomplished by a combination of hypermutation and gene conversion if homologous conversion donor sequences are inserted upstream of the transgene. It has already been demonstrated that gene conversion can be used for the diversification of transgenes in DT40 ([@B20]).

The high efficiency of targeted gene integration in DT40 allows one to standardize the hypermutation of transgenes and the confirmation of mutant phenotypes ([Figure 5](#F5){ref-type="fig"}). We envision that the transgene of interest is first cloned into the *pHypermut2* vector and then transfected into a DT40 clone which conditionally expresses AID. Transfectants, which hypermutate the transgene after targeted integration into the rearranged *Ig light chain* locus, are subjected to iterative cycles of cell selection and expansion. When a cell population of the desired phenotype is isolated, hypermutation is shut off by excision of the *AID* expression cassette and the cells are subcloned. Transgene sequences from the most promising subclones are amplified by PCR and cloned into the *pHypermut2* vector for sequencing. In the end, the mutated transgenes within the pHypermut2 vector are transfected back into AID negative cells to verify their phenotype. Figure 5.Scheme of artificial evolution in DT40. The approach only requires a cell line such as AID^R^ which conditionally expresses AID and the *pHypermut2* targeting vector.

In principle, DT40 can be used for the evolution of any coding or non-coding sequence whose transcription is tolerated. However, evolution of transgenes encoding non-fluorescent proteins is only feasible, if rare cells carrying desirable mutations can be enriched from the bulk culture. As FACS sorting is ideal for selection, one might attempt to tie the optimization of non-fluorescent proteins to fluorescent signals. For example, a cell surface receptor expressed on the surface of DT40 might be optimized using a fluorescent coupled ligand. Most likely, the selection strategies will need to be customized for different types of proteins and the outcome of these efforts will determine the success of artificial evolution in DT40.
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